Nextleaf Solutions Awarded U.S. Patent for Synthesizing THC-O-Acetate

3.6 min readPublished On: April 15th, 2021By

VANCOUVER, B.C.– Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA), the world’s most innovative cannabis processor, announced that the United States Patent and Trademark Office has granted the Company a patent pertaining to a novel synthetic route of modifying Tetrahydrocannabinol found in cannabis distillate into a more potent prodrug version of THC-O-acetate.

The Company believes the THC-derived prodrug produced under its patented process may hold significant potential as a therapeutic product due to THC-O-acetate reportedly having pronounced psychedelic effects compared to THC, and positive outcomes in the treatment of chronic pain, PTSD, and alcohol use disorder.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5347/80520_2f157d3124177a4f_001.jpg

(left to right) Dr. Xuan Jia, Paul Pedersen, Ryan Ko, Dr. David Novitski, Keenan Sindia

“The U.S. continues to be the focal point of our global IP strategy,” said Nextleaf CEO Paul Pedersen. “Between operating our cannabinoid innovation lab under strict federal regulations in Canada where cannabis is federally legal and owning one of the largest U.S. patent portfolios of any cannabis company, Nextleaf has the type of robust intellectual property portfolio and scalable commercial platform that large pharmaceuticals and big tobacco companies have already targeted with M&A in 2021.”

On March 31, 2021 New York became the 16th state to legalize cannabis. The event increases pressure on the United States to progress federal marijuana reform and it is expected that legislation will be reintroduced and voted on with the Senate Majority Leader Chuck Schumer leading the way.

“This U.S. patent covers our method of THC acetylation and follows our previous patent for synthesizing THC-O-acetate, with improvements to reaction efficiencies,” said Nextleaf Solutions R&D Lead, Dr. David Novitski. “Our latest patented method reduces processing time and costs, which are critical when scaling up any drug delivery technology, and THC-O-acetate is no different.”

Nextleaf is exploring opportunities to commercialize this patent through IP licensing to a pharmaceutical partner or producing and distributing THC-O-acetate as a therapeutic product under the Company’s Health Canada licenses.

“To the best of our knowledge, Nextleaf is the first company in the world, publicly traded or private, to be issued patents for the production of THC-O-Acetate, a specialty molecule not legally available anywhere in the world,” said Pedersen (pictured).

Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its IP portfolio, the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

 

(This information is primarily sourced from Nextleaf.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here)

 

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

  • CBD Oil Market, CBD Skin Care Market, Industrial hemp Market, Medical Marijuana Market, Financial Results

CBD Oil Market to Register 31.50% CAGR by 2031

December 3rd, 2022|

NEWARK, Del - The global cannabidiol CBD oil market is anticipated to grow at an impressive compound annual growth rate (CAGR) of 31.50% annually over the projection period from 2021 to 2031. The global market ...